GlassScriptPhysician profile
Cathy Milam
NPI 1912968694
$1,562.06
in general payments reported to CMS, 2019-2025
15 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $25.07 · 2021: $15.40 · 2022: $181 · 2023: $269 · 2024: $403 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $400.89 | 2019 | |
| Biofrontera INC. | $252.81 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Abbvie INC. | $200.23 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $167.12 | 2024-2025 | |
| Ucb, INC. | $157.81 | 2024 | Bimzelx |
| Genentech USA, INC. | $112.44 | 2019 | |
| Galderma Laboratories, L.P. | $77.66 | 2022-2025 | Nemluvio |
| Allergan, INC. | $60.63 | 2019-2022 | |
| Leo Pharma INC. | $27.82 | 2022 | |
| Dermavant Sciences, INC. | $20.89 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $19.76 | 2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.04 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.59 | 2019 | |
| Janssen Biotech, INC. | $16.49 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Milam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.